

NATIONAL BLOOD AUTHORITY

Entity Resources and Planned Performance

NATIONAL BLOOD AUTHORITY

Section 1: Entity Overview and Resources	344
1.1 Strategic Direction Statement	344
1.2 Entity Resource Statement	345
1.3 Budget Measures	347
Section 2: Outcomes and Planned Performance	348
2.1 Budgeted Expenses and Performance for Outcome 1	348
Section 3: Budgeted Financial Statements	354
3.1 Budgeted Financial Statements	354
3.2 Budgeted Financial Statements Tables	356



Section 1: Entity Overview and Resources

1.1 STRATEGIC DIRECTION STATEMENT¹

The Australian Government, through the National Blood Authority (NBA), aims to ensure that Australia has an adequate, safe, secure and well-managed blood supply. The NBA was established by the Australian Government, and State and Territory Governments, to coordinate policy, governance, funding and management of the blood and blood product sector in Australia.

The NBA manages national contracts to secure the supply of safe and affordable blood products in Australia in accordance with the National Blood Agreement. The NBA works with governments and stakeholders to implement an efficient, demand-driven blood supply system that is highly responsive to clinical needs and based upon evidence and good clinical practice. The purchasing and supply arrangements for fresh, fractionated and recombinant blood products² will continue to be improved, including further strengthening risk mitigation arrangements.

The NBA will continue to undertake a range of activities aimed at improving the clinical use of blood and blood products in recognition of the growing cost of blood products and the growing evidence of risk associated with unnecessary transfusions. Specifically, the NBA aims to improve the sustainability and performance of the sector through: enhanced data capture and analysis; improved governance of access to immunoglobulin products to ensure the most cost-effective use of limited and high cost products; and facilitate the development and publication of evidence-based national clinical practice guidelines, informed by close engagement with clinicians.

The role and functions of the NBA are set out in the *National Blood Authority Act 2003*. The NBA is a non-corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013*.

¹ For more information about the strategic direction of the NBA, refer to the current Corporate Plan, available at: www.blood.gov.au/system/files/documents/NBA-Corporate-Plan-2017-18-to-2020-21.pdf

² Fractionated products are those derived from human plasma whereas recombinant products are those manufactured through commercial scale expression of proteins from cell lines modified using recombinant gene technology.

1.2 ENTITY RESOURCE STATEMENT

Table 1.1 shows the total funding from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (Government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity's operations) classification.

For more detailed information on special accounts and special appropriations, refer to *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (i.e. appropriations/cash available) basis, whilst the 'Budgeted expenses by outcome' tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis.

Table 1.1: NBA Resource Statement – Budget Estimates for 2018-19 as at Budget May 2018

	2017-18 Estimated actual \$'000	2018-19 Estimate \$'000
DEPARTMENTAL		
Prior year appropriation available	10,524	8,746
Annual appropriations		
Ordinary annual services ^(a)		
Departmental appropriation	5,590	5,682
s74 retained revenue receipts ^(b)	-	-
Departmental capital budget ^(c)	621	617
Other services ^(d)		
Equity injection	-	-
Total departmental annual appropriations	6,211	6,299
Special Accounts ^(e)		
Appropriation receipts	6,211	6,299
Non-appropriation receipts	3,867	3,949
Total special account	10,078	10,248
Less appropriations drawn from annual or special appropriations above and credited to Special Accounts ^(f)	(6,211)	(6,299)
Total departmental resourcing	20,602	18,994

NBA

Table 1.1: NBA Resource Statement – Budget Estimates for 2018-19 as at Budget May 2018 (continued)

	2017-18 Estimated actual \$'000	2018-19 Estimate \$'000
ADMINISTERED		
Prior year appropriation available	123,526	155,441
Annual appropriations		
Ordinary annual services ^(a)		
Outcome 1	3,860	3,404
Other services ^(d)		
Administered assets and liabilities	-	-
Total administered annual appropriations	3,860	3,404
Special Accounts ^(e)		
Appropriation receipts	3,860	3,404
Appropriation receipts - other entities ^(g)	718,621	782,766
Non-appropriation receipts	433,885	473,010
Total Special Accounts	1,156,366	1,259,180
Less appropriations drawn from annual or special appropriations above and credited to Special Accounts ^(f)	(3,860)	(3,404)
Total administered resourcing	1,279,892	1,414,621
Total resourcing for NBA	1,300,494	1,433,615
	2017-18	2018-19
Average staffing level (number)	53	54

All figures are GST exclusive.

^(a) Appropriation Bill (No. 1) 2018-19.

^(b) Estimated retained revenue receipts under section 74 of the PGPA Act 2013.

^(c) Departmental Capital Budgets (DCB) are not separately identified in Appropriation Bill (No. 1) and form part of ordinary annual services items. Refer to Table 3.5 for further details. For accounting purposes, this amount has been designated as a 'contribution by owner'.

^(d) Appropriation Bill (No. 2) 2018-19.

^(e) For further information on special appropriations and special accounts, refer to *Budget Paper No. 4 - Agency Resourcing*. Also see Table 2.1 for further information on outcome and program expenses broken down by various funding sources, e.g. annual appropriations, special appropriations and special accounts.

^(f) Appropriation receipts included above.

^(g) Appropriation receipts from the Department of Health.

1.3 BUDGET MEASURES

Budget measures in Part 1 relating to the NBA are detailed in Budget Paper No. 2 and are summarised below.

Table 1.2: NBA 2018-19 Budget Measures

Program		2017-18 \$'000	2018-19 \$'000	2019-20 \$'000	2020-21 \$'000	2021-22 \$'000
Improving Access to Medicines - strengthening the quality use of healthcare services ^(a)						
National Blood Authority						
Administered expenses	1.1	-	(2,222)	(5,484)	(17,340)	(17,778)
Administered revenue ^(b)	1.1	-	822	2,029	6,416	6,577
Total		-	(1,400)	(3,455)	(10,924)	(11,201)

^(a) Full details of this measure are published under Department of Health (Table 1.2)

^(b) Revenue is reverse fiscal and shows the net fiscal position



Section 2: Outcomes and Planned Performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which Government entities achieve the intended results of their outcome statements. Entities are required to identify the programs that contribute to Government outcomes over the Budget and forward years.

Each outcome is described below together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

Note:

Performance reporting requirements in the Portfolio Budget Statements are part of the enhanced Commonwealth performance framework established by the *Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance criteria described in Portfolio Budget Statements will be read with broader information provided in an entity's Corporate Plans and Annual Performance Statements – included in Annual Reports – to provide an entity's complete performance story.

The NBA's most recent Corporate Plan is available at:
www.blood.gov.au/about-nba

The NBA's most recent Annual Performance Statement is available at:
www.blood.gov.au/pubs/1617report.v2/index.html

2.1 BUDGETED EXPENSES AND PERFORMANCE

Outcome 1

Access to a secure supply of safe and affordable blood products, including through national supply arrangements and coordination of best practice standards within agreed funding policies under the national blood arrangements

Program Contributing to Outcome 1

Program 1.1: National Blood Agreement Management

Linked Programs

Other Commonwealth entities that contribute to Outcome 1
<p>Australian Commission on Safety and Quality in Health Care Program 1.1: Safety and Quality in Health Care</p> <p>The Australian Commission on Safety and Quality in Health Care works closely with the National Blood Authority in relation to the <i>National Safety and Quality Health Service Standard 7: Blood Management</i>. This supports the National Blood Authority in administering the National Blood Agreement.</p>
<p>Department of Health Program 1.1: Health Policy Research and Analysis</p> <p>The Department of Health, in collaboration with State and Territory health departments, has policy responsibility for ensuring Australians have access to an adequate, safe, secure and affordable blood supply. This includes supporting the National Blood Authority to administer the national blood arrangements.</p>



Budgeted Expenses for the NBA

Table 2.1.1 shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by administered and departmental funding sources.

Table 2.1.1: Budgeted Expenses for the NBA

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Year 1 \$'000	2020-21 Forward Year 2 \$'000	2021-22 Forward Year 3 \$'000
Program 1.1: National Blood Agreement Management					
Administered expenses					
Ordinary annual services ^(a)	3,860	3,404	-	-	-
<i>to National Blood Authority Account</i>	(3,860)	(3,404)	-	-	-
<i>to National Managed Fund (Blood and Blood Products) Special Account</i>	-	-	-	-	-
Special Accounts					
<i>National Blood Authority Account</i>	1,171,220	1,253,439	1,333,794	1,445,933	1,578,877
<i>National Managed Fund (Blood and Blood Products) Special Account</i>	-	-	-	-	-
Departmental expenses					
Departmental appropriation ^(b)	5,590	5,682	5,686	5,531	5,562
<i>to National Blood Authority Account</i>	(5,590)	(5,682)	(5,686)	(5,531)	(5,562)
Special Accounts					
<i>National Blood Authority Account</i>	9,457	9,631	9,638	9,409	9,460
Expenses not requiring appropriation in the Budget year ^(c)	418	392	592	559	559
Operating deficit (surplus)	1,784	-	-	-	-
Total for Program 1.1	1,182,879	1,263,462	1,344,024	1,455,901	1,588,896
Total expenses for Outcome 1	1,182,879	1,263,462	1,344,024	1,455,901	1,588,896

	2017-18	2018-19
Average staffing level (number)	53	54

^(a) Appropriation (Bill No. 1) 2018-19.

^(b) Departmental appropriation combines 'Ordinary annual services (Appropriation Bill No. 1)' and 'Revenue from independent sources (s74)'.

^(c) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expense and audit fees.

Movement of Funds

There were no movements of Administered funds between years.

Planned Performance for the NBA

Table 2.1.2 below details the performance criteria for the program associated with Outcome 1. It also summarises how the program is delivered and where 2018-19 Budget measures have materially changed the program.

Table 2.1.2: Performance Criteria for the NBA

Purpose
Saving and improving Australian lives through a world-class blood supply.
Outcome 1
Access to a secure supply of safe and affordable blood products, including through national supply arrangements and coordination of best practice standards within agreed funding policies under the national blood arrangements.
Program 1.1: National Blood Agreement Management
The NBA, on behalf of the Australian Government and State and Territory Governments, manages and coordinates national contracts to secure the supply of safe and affordable blood products in Australia in accordance with the National Blood Agreement.
Delivery
<p>A. Providing a safe, secure and affordable supply of blood and blood-related products and services</p> <ul style="list-style-type: none"> • Continue implementation of the Immunoglobulin Governance Program. • Finalise and implement the revised <i>National Blood Supply Contingency Plan</i>. • Implement the <i>National Blood Product Management Improvement Strategy 2018–22</i>. <p>B. Driving performance improvement in the Australian blood sector</p> <ul style="list-style-type: none"> • Implement the revised <i>National ICT and Data Strategy</i>. • Finalise the implementation of BloodNet interfaces with hospital laboratory information systems. • Implement the <i>Immunoglobulin Performance Improvement Strategy</i>. • Establish immunoglobulin governance performance indicators and reporting. <p>C. Promoting a best practice model of management and use of blood and blood-related products and services</p> <ul style="list-style-type: none"> • Develop and promote an expanded suite of tools to support health providers to implement the National Safety Quality Health Services Blood Management Standards. • Continue the review and revision of criteria for access to immunoglobulin products under the national blood arrangements. • Develop and support health technology assessment and utilisation review processes for immunoglobulin and other existing and proposed new blood products. • Revise and publish updated modules of the <i>National Patient Blood Management Guidelines</i>.



Performance criteria				
A. Providing a safe, secure and affordable supply of blood and blood-related products and services				
Provision of an adequate, affordable and secure supply of blood and blood-related products.				
2017-18 Estimated result	2018-19 Target		2019-20 (& beyond) Target	
Supply for clinical need has been met within the requirements of the approved 2017-18 National Supply Plan and Budget. There have been no contingency events and no product shortages reported.	Blood products are available to meet clinical need.		As per 2018-19.	
Variance between actual and budget is kept to a minimum both in monetary and product volumes.				
2017-18 Estimated result	2018-19 Target	2019-20 Target	2020-21 Target	2021-22 Target
<5%	<5%	<5%	<5%	<5%
Minimise wastage to ensure availability of product to meet clinical demand.				
2017-18 Estimated result	2018-19 Target	2019-20 Target	2020-21 Target	2021-22 Target
<3%	<3%	<3%	<3%	<3%
B. Driving performance improvement in the Australian blood sector				
National data and ICT strategy and <i>National Patient Blood Management Guidelines Implementation Strategy 2017–21</i> are progressed.				
2017-18 Estimated result	2018-19 Target		2019-20 (& beyond) Target	
The National Data and ICT strategy was developed and <i>The Patient Blood Management Implementation Strategy 2017–21</i> was executed.	Strategies are progressed and results published against the expected outcomes in the strategies.		As per 2018-19.	
Percentage of national blood supply processed by laboratories interfaced to BloodNet.				
2017-18 Estimated result	2018-19 Target	2019-20 Target	2020-21 Target	2021-22 Target
60%	≥60%	≥80%	≥85%	≥85%

C. Promoting a best practice model of management and use of blood and blood-related products and services		
Support best practice management and use of blood and blood-related products through a robust framework.		
2017-18 Estimated result	2018-19 Target	2019-20 (& beyond) Target
<p>Sustained improvements in the management and use of blood products by:</p> <ul style="list-style-type: none"> – reduction in wastage in comparison to the 2016-17 result; and – improvement in the delivery schedule for fresh products as a result of a reduction in the number of orders by health providers. 	<p>Sustain improvements in the management and use of blood products by:</p> <ul style="list-style-type: none"> – improving inventory management practices as part of the National Inventory Management Framework rollout; – reducing wastage in comparison to the 2017-18 result; and – improving the delivery schedule for fresh products by a reduction in the number of orders by health providers. 	As per 2018-19.
Support clinicians to use best practice models for the management and use of blood and blood products.		
2017-18 Estimated result	2018-19 Target	2019-20 (& beyond) Target
<p>A number of clinical guidelines, clinical practice tools and resources have been developed, updated and promoted for use within the sector.</p> <p>The revised guideline project was advanced and outcomes endorsed by the Jurisdictional Blood Committee in 2018.</p>	<p>Update, develop and promote a number of clinical guidelines, clinical practice tools and resources for use within the sector.</p> <p>One guideline in 2018-19.</p>	As per 2018-19.
Material changes to Program 1.1 resulting from the following measures:		
There are no material changes to Program 1.1 resulting from measures.		



Section 3: Budgeted Financial Statements

Section 3 presents budgeted financial statements that provide a comprehensive snapshot of entity finances for the 2018-19 Budget year, including the impact of Budget measures and resourcing on financial statements.

3.1 BUDGETED FINANCIAL STATEMENTS

3.1.1 Differences Between Entity Resourcing and Financial Statements

This section is not applicable to the NBA.

3.1.2 Explanatory Notes and Analysis of Budgeted Financial Statements

Departmental Resources

Comprehensive Income Statement

This statement illustrates the expected financial results for the NBA by identifying accrual expenses and revenues showing the net cost of services.

The NBA's operational costs are funded jointly by the Australian Government and State and Territory Governments, on a 63 per cent: 37 per cent basis via annual contributions. All NBA receipts and payments are accounted for through special accounts.

The NBA has an approved operating loss of \$1.784 million in 2017-18. This is offset against surplus operating funds from prior years. This operating loss reflects additional expenditure incurred by the NBA to strengthen cyber-security, improve contract management arrangements and governance for contracted personnel and to provide additional support and maintenance for a national system that supports and governs the use of nationally funded immunoglobulin.

The income statement deficit in the Budget year and forward years is as a result of the Government's decision to no longer fund for depreciation via an operating appropriation.

Balance Sheet

Special account accumulated funds are held within the Official Public Account and included as Cash and cash equivalents in the Balance Sheet. The NBA always maintains sufficient accumulated funds to cover employee entitlements and other liabilities.

The value of intangible assets increases from 2018-19 onwards due to the development of replacement systems. Other non-financial assets and liabilities will remain broadly stable over the period.

Administered Resources

Schedule of Budgeted Income and Expenses Administered on Behalf of Government

The NBA's administered accounts include contributions from all States and Territories and the Australian Government for the supply of blood and blood related products for 2018-19. Each year the Council of Australian Governments' Health Council approves an Annual National Supply Plan and Budget which is formulated by the NBA, derived from demand estimates provided by the States and Territories.

Schedule of Budgeted Assets and Liabilities Administered on Behalf of Government

The schedule of budgeted assets and liabilities administered on behalf of Government illustrates normal movements in non-financial assets and liabilities. Special account accumulated funds are held within the Official Public Account and included as Cash and cash equivalents in the Balance Sheet. The balance of Receivables represents GST payments made to suppliers which are recoverable from the Australian Taxation Office. Other non-financial assets represent a prepayment to the Australian Red Cross Blood Service under the Output Based Funding Model agreement.

3.2 BUDGETED FINANCIAL STATEMENTS TABLES

Table 3.1: Comprehensive Income Statement (showing net cost of services for the period ended 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Year 1 \$'000	2020-21 Forward Year 2 \$'000	2021-22 Forward Year 3 \$'000
EXPENSES					
Employee benefits	6,630	6,500	6,591	6,639	6,712
Supplier expenses	4,686	3,206	3,121	2,844	2,822
Depreciation and amortisation	337	311	511	478	478
Finance costs	6	6	7	7	7
Total expenses	11,659	10,023	10,230	9,968	10,019
LESS:					
OWN-SOURCE INCOME					
Revenue					
Sale of goods and rendering of services	250	250	250	250	250
Other revenue	3,617	3,699	3,702	3,628	3,648
Total revenue	3,867	3,949	3,952	3,878	3,898
Gains					
Other	81	81	81	81	81
Total gains	81	81	81	81	81
Total own-source income	3,948	4,030	4,033	3,959	3,979
Net cost of (contribution by) services	7,711	5,993	6,197	6,009	6,040
Revenue from Government	5,590	5,682	5,686	5,531	5,562
Surplus (deficit)	(2,121)	(311)	(511)	(478)	(478)
Surplus (deficit) attributable to the Australian Government	(2,121)	(311)	(511)	(478)	(478)
OTHER COMPREHENSIVE INCOME					
Changes in asset revaluation reserves	-	-	-	-	-
Total other comprehensive income	-	-	-	-	-
Total comprehensive income attributable to the Australian Government	(2,121)	(311)	(511)	(478)	(478)
Note: Reconciliation of comprehensive income attributable to the agency					
	2017-18 \$'000	2018-19 \$'000	2019-20 \$'000	2020-21 \$'000	2021-22 \$'000
Total comprehensive income (loss) attributable to the Australian Government	(2,121)	(311)	(511)	(478)	(478)
plus non-appropriated expenses depreciation and amortisation expenses	337	311	511	478	478
Total comprehensive income (loss) attributable to the agency	(1,784)	-	-	-	-

Table 3.2: Budgeted Departmental Balance Sheet (as at 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Year 1 \$'000	2020-21 Forward Year 2 \$'000	2021-22 Forward Year 3 \$'000
ASSETS					
Financial assets					
Cash and cash equivalents	8,746	8,752	8,765	8,772	8,779
Receivables	125	125	125	125	125
Total financial assets	8,871	8,877	8,890	8,897	8,904
Non-financial assets					
Land and buildings	700	568	436	337	238
Property, plant and equipment	402	433	414	375	336
Intangibles	527	934	1,192	1,499	1,809
Other	168	168	168	168	168
Total non-financial assets	1,797	2,103	2,210	2,379	2,551
Total assets	10,668	10,980	11,100	11,276	11,455
LIABILITIES					
Payables					
Suppliers	384	384	390	390	390
Other payables	616	616	616	616	616
Total payables	1,000	1,000	1,006	1,006	1,006
Provisions					
Employees	1,892	1,892	1,892	1,892	1,892
Other provisions	149	155	162	169	176
Total provisions	2,041	2,047	2,054	2,061	2,068
Total liabilities	3,041	3,047	3,060	3,067	3,074
Net Assets	7,627	7,933	8,040	8,209	8,381
EQUITY					
Contributed equity	4,565	5,182	5,800	6,447	7,097
Reserves	460	460	460	460	460
Retained surpluses or accumulated deficits	2,602	2,291	1,780	1,302	824
Total equity	7,627	7,933	8,040	8,209	8,381

Table 3.3: Departmental Statement of Changes in Equity – Summary of Movement (Budget year 2018-19)

	Retained earnings	Asset revaluation reserve	Contributed equity/ capital	Total equity
	\$'000	\$'000	\$'000	\$'000
Opening balance as at 1 July 2018				
Balance carried forward from previous period	2,602	460	4,565	7,627
Surplus (deficit) for the period	(311)	-	-	(311)
Appropriation (equity injection)	-	-	-	-
Capital budget - Bill 1 (DCB)	-	-	617	617
Estimated closing balance as at 30 June 2019	2,291	460	5,182	7,933

DCB = Departmental Capital Budget.

Table 3.4: Budgeted Departmental Statement of Cash Flows (for the period ended 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Estimate \$'000	2020-21 Forward Estimate \$'000	2021-22 Forward Estimate \$'000
OPERATING ACTIVITIES					
Cash received					
Appropriations	5,590	5,682	5,686	5,531	5,562
Good and Services	250	250	250	250	250
Net GST received	460	313	303	276	274
Other cash received	3,617	3,699	3,702	3,628	3,648
Cash from the Official Public Account					
Total cash received	9,917	9,944	9,941	9,685	9,734
Cash used					
Employees	6,630	6,500	6,591	6,639	6,712
Suppliers	4,605	3,125	3,034	2,763	2,741
Net GST paid	460	313	303	276	274
Cash to the Official Public Account	-	-	-	-	-
Total cash used	11,695	9,938	9,928	9,678	9,727
Net cash from (or used by) operating activities	(1,778)	6	13	7	7
INVESTING ACTIVITIES					
Cash used					
Purchase of property, plant and equipment	621	617	618	647	650
Total cash used	621	617	618	647	650
Net cash from (or used by) investing activities	(621)	(617)	(618)	(647)	(650)
FINANCING ACTIVITIES					
Cash received					
Capital budget - Bill 1 (DCB)	621	617	618	647	650
Total cash received	621	617	618	647	650
Net cash from (or used by) financing activities	621	617	618	647	650
Net increase (or decrease) in cash held	(1,778)	6	13	7	7
Cash and cash equivalents at the beginning of the reporting period	10,524	8,746	8,752	8,765	8,772
Cash and cash equivalents at the end of the reporting period	8,746	8,752	8,765	8,772	8,779

DCB = Departmental Capital Budget.



Table 3.5: Departmental Capital Budget Statement (for the period ended 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Estimate \$'000	2020-21 Forward Estimate \$'000	2021-22 Forward Estimate \$'000
CAPITAL APPROPRIATIONS					
Capital budget - Bill 1 (DCB)	621	617	618	647	650
Total capital appropriations	621	617	618	647	650
Total new capital appropriations represented by:					
Purchase of non-financial assets	621	617	618	647	650
Total items	621	617	618	647	650
PURCHASE OF NON-FINANCIAL ASSETS					
Funded by capital appropriation - DCB ^(a)	621	617	618	647	650
Funded internally from departmental resources	-	-	-	-	-
Total acquisitions of non-financial assets	621	617	618	647	650
RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE					
Total purchases	621	617	618	647	650
Total cash used to acquire assets	621	617	618	647	650

DCB = Departmental Capital Budget.

^(a) Does not include annual finance lease costs. Includes purchases from current and previous years' Departmental Capital Budgets (DCB).

Table 3.6: Statement of Asset Movements (Budget year 2018-19)

	Buildings	Other property, plant and equipment	Intangibles	Total
	\$'000	\$'000	\$'000	\$'000
As at 1 July 2018				
Gross book value	864	593	4,072	5,529
Accumulated depreciation/ amortisation and impairment	(164)	(191)	(3,545)	(3,900)
Opening net book balance	700	402	527	1,629
CAPITAL ASSET ADDITIONS				
Estimated expenditure on new or replacement assets				
By purchase - appropriation equity	-	-	-	-
By purchase - appropriation ordinary annual services	-	150	467	617
By purchase - internal resources	-	-	-	-
Total additions	-	150	467	617
Other movements				
Depreciation/amortisation expense	(132)	(119)	(60)	(311)
Total other movements	(132)	(119)	(60)	(311)
As at 30 June 2019				
Gross book value	864	743	4,539	6,146
Accumulated depreciation/ amortisation and impairment	(296)	(310)	(3,605)	(4,211)
Closing net book balance	568	433	934	1,935

Table 3.7: Schedule of Budgeted Income and Expenses Administered on Behalf of Government (for the period ended 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Estimate \$'000	2020-21 Forward Estimate \$'000	2021-22 Forward Estimate \$'000
EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT					
Employee benefits	634	634	-	-	-
Suppliers	1,169,411	1,251,630	1,333,794	1,445,933	1,578,877
Grants	500	500	-	-	-
Depreciation and amortisation	675	675	-	-	-
Total expenses administered on behalf of Government	1,171,220	1,253,439	1,333,794	1,445,933	1,578,877
INCOME ADMINISTERED ON BEHALF OF GOVERNMENT					
Revenue					
Non-taxation					
Other sources of non-taxation revenues	1,152,506	1,255,776	1,337,940	1,450,079	1,583,023
Total non-taxation revenue	1,152,506	1,255,776	1,337,940	1,450,079	1,583,023
Total revenues administered on behalf of Government	1,152,506	1,255,776	1,337,940	1,450,079	1,583,023
Total income administered on behalf of Government	1,152,506	1,255,776	1,337,940	1,450,079	1,583,023

Table 3.8: Schedule of Budgeted Assets and Liabilities Administered on Behalf of Government (as at 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Estimate \$'000	2020-21 Forward Estimate \$'000	2021-22 Forward Estimate \$'000
ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT					
Financial assets					
Cash and cash equivalent	155,441	153,357	153,357	153,357	153,357
Receivables	21,307	21,307	21,307	21,307	21,307
Investments	127,246	131,392	135,538	139,684	143,830
Total financial assets	303,994	306,056	310,202	314,348	318,494
Non-financial assets					
Property, plant and equipment	93	83	83	83	83
Intangibles	3,286	3,571	3,571	3,571	3,571
Inventories	95,125	95,125	95,125	95,125	95,125
Other	76,064	76,064	76,064	76,064	76,064
Total non-financial assets	174,568	174,843	174,843	174,843	174,843
Total assets administered on behalf of Government	478,562	480,899	485,045	489,191	493,337
LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT					
Interest bearing liabilities					
Payables					
Suppliers	53,843	53,843	53,843	53,843	53,843
Total payables	53,843	53,843	53,843	53,843	53,843
Total liabilities administered on behalf of Government	53,843	53,843	53,843	53,843	53,843

Table 3.9: Schedule of Budgeted Administered Cash Flows (for the period ended 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Estimate \$'000	2020-21 Forward Estimate \$'000	2021-22 Forward Estimate \$'000
OPERATING ACTIVITIES					
Cash received					
Commonwealth contributions	718,621	782,766	834,415	904,945	988,577
State and Territory contributions	429,739	468,864	499,379	540,988	590,300
Interest	4,146	4,146	4,146	4,146	4,146
Net GST received	116,941	125,385	133,928	146,327	159,666
Total cash received	1,269,447	1,381,161	1,471,868	1,596,406	1,742,689
Cash used					
Employees	634	634	-	-	-
Suppliers	1,169,411	1,255,034	1,333,794	1,445,933	1,578,877
Grant payments	500	500	-	-	-
Net GST paid	117,775	125,385	133,928	146,327	159,666
Total cash used	1,288,320	1,381,553	1,467,722	1,592,260	1,738,543
Net cash from (or used by) operating activities	(18,873)	(392)	4,146	4,146	4,146
INVESTING ACTIVITIES					
Cash received					
Proceeds from sale of investments	-	-	-	-	-
Total cash received	-	-	-	-	-
Cash used					
Purchase of investments	4,146	4,146	4,146	4,146	4,146
Purchase of non-financial assets	950	950	-	-	-
Total cash used	5,096	5,096	4,146	4,146	4,146
Net cash from (or used by) investing activities	(5,096)	(5,096)	(4,146)	(4,146)	(4,146)
Net increase (or decrease) in cash held	(23,969)	(5,488)	-	-	-
Cash at beginning of reporting period	175,550	155,441	153,357	153,357	153,357
Cash from Official Public Account for:					
- appropriations	3,860	3,404	-	-	-
Cash at end of reporting period	155,441	153,357	153,357	153,357	153,357

Table 3.10: Schedule of Administered Capital Budget

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Estimate \$'000	2020-21 Forward Estimate \$'000	2021-22 Forward Estimate \$'000
CAPITAL APPROPRIATIONS					
Capital budget - Bill 1 (DCB)	-	-	-	-	-
Total capital appropriations	-	-	-	-	-
Total new capital appropriations represented by:					
Purchase of non-financial assets	-	-	-	-	-
Total items	-	-	-	-	-
PURCHASE OF NON-FINANCIAL ASSETS					
Funded by capital appropriation - DCB ^(a)	-	-	-	-	-
Funded internally from departmental resources	950	950	-	-	-
Total acquisitions of non-financial assets	950	950	-	-	-
RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE					
Total purchases	950	950	-	-	-
Total cash used to acquire assets	950	950	-	-	-

DCB = Departmental Capital Budget.

^(a) Does not include annual finance lease costs. Includes purchases from current and previous years' Departmental Capital Budgets (DCB).



Table 3.11: Statement of Administered Asset Movements (Budget Year 2018-19)

	Buildings \$'000	Other property, plant and equipment \$'000	Intangibles \$'000	Total \$'000
As at 1 July 2017				
Gross book value	-	167	6,282	6,449
Accumulated depreciation/ amortisation and impairment	-	(74)	(2,996)	(3,070)
Opening net book balance	-	93	3,286	3,379
CAPITAL ASSET ADDITIONS				
Estimated expenditure on new or replacement assets				
By purchase - appropriation equity	-	-	-	-
By purchase - appropriation ordinary annual services	-	-	-	-
By purchase - internal resources	-	50	900	950
Total additions	-	50	900	950
Other movements				
Depreciation/amortisation expense	-	(60)	(615)	(675)
Total other movements	-	(60)	(615)	(675)
As at 30 June 2018				
Gross book value	-	217	7,182	7,399
Accumulated depreciation/ amortisation and impairment	-	(134)	(3,611)	(3,745)
Closing net book balance	-	83	3,571	3,654